NCT05029258 (Bio-CHECC) is a clinical trial of Biopsy of tumour in Cervical Cancer, sponsored by University of Manchester.

Who is sponsoring NCT05029258?

NCT05029258 is sponsored by University of Manchester.

What drugs are being tested in NCT05029258?

Interventions in NCT05029258: Biopsy of tumour, MRI scans.

What condition does NCT05029258 study?

NCT05029258 studies Cervical Cancer.

Is NCT05029258 still recruiting?

NCT05029258 is currently recruiting now. Last updated 20 January 2025.

Last reviewed 2025-01-20 · How we verify

NCT05029258: Bio-CHECC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer

Recruiting now Last updated 20 January 2025

What this trial tests

trial testing Biopsy of tumour in Cervical Cancer in 30 participants. Currently enrolling.

Timeline

10 December 2020

Primary endpoint
31 October 2027

31 October 2027

Quick facts

Lead sponsor	University of Manchester
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	30
Start date	10 December 2020
Primary completion	31 October 2027
Estimated completion	31 October 2027
Sites	1 location across United Kingdom

Drugs / interventions tested

Biopsy of tumour
MRI scans

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

University of Manchester

Who can join

18 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with locally advanced cervical cancer (LACC) are primarily treated with radiotherapy +/- chemotherapy however 5-year survival rates are \<60% with significant treatment toxicity. Hypoxia is a well-known radioresistant component of solid tumours such as cervical cancer and hypoxia modification therapies have demonstrated immense promise in treating such tumours. A major factor in determining a successful outcome with hypoxia modification is appropriate patient selection as it is hypoxic tumours that receive the most benefit from hypoxia modifying therapies. To date there is no validated hypoxia biomarker to stratify patients for therapy in cervical cancer in clinical use. This project offers a unique opportunity to examine both genetic and imaging biomarkers to optimise patient stratification when receiving curative radiotherapy for cervical cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pancreatic Ductal Adenocarcinoma: The Characteristics of Contrast-Enhanced Ultrasound Are Correlated with the Hypoxic Microenvironment.
Wang L, Li M, Dong T, Li Y, et al · · 2023 · cited 4× · PMID 37892091 · DOI 10.3390/diagnostics13203270

Verify or expand the search:

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other University of Manchester trials

Trials by the same sponsor.

NCT07506096 — Using IF-THEN Plans to Support Healthcare Professionals in Raising Patient Safety Concerns · NA · not yet recruiting
NCT07084090 — Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care · NA · not yet recruiting
NCT07494760 — A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experien · NA · not yet recruiting
NCT07372885 — GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia · Phase 1, PHASE2 · not yet recruiting
NCT07381894 — Multicentre Hypertrophic Cardiomyopathy Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05029258 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manchester
Last refreshed: 20 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05029258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing